Compare AU
Compare GCAP vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are GCAP and DRUG. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
GCAP | DRUG | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 64 |
Median incremental investment | $0 | $882.72 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,967.19 |
Average age group | N/A | 26 - 35 |
Key Summary
GCAP | DRUG | |
|---|---|---|
Strategy | GCAP.AX was created on 2021-08-03 by VanEck. The fund's investment portfolio concentrates primarily on investment grade fixed income. GCAP.AX aims to provide investors with a professionally managed active strategy in global Capital Securities. The fund aims to provide total investment returns, measured over the long term in excess of the Benchmark. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | VanEck Bentham Gbl Capital Securities Active ETF (100 %) | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Other (76.17 %) Communication Services (33.53 %) Health Care (23.66 %) | |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 0.59 % | 0.57 % |
Key Summary
GCAP | DRUG | |
|---|---|---|
Issuer | VanEck | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 0.59 % | 0.57 % |
Price | $8.77 | $7.61 |
Size | $29.312 million | $167.407 million |
10Y return | N/A | N/A |
Annual dividend/ distribution yield (5Y) | 3.94 % | 1.89 % |
Market | ASX | ASX |
First listed date | 04/08/2021 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
GCAP | DRUG | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 64 |
Median incremental investment | $0 | $882.72 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,967.19 |
Average age group | N/A | 26 - 35 |
Pros and Cons
GCAP | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
GCAP | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |